Cargando…
The journey of omega-3 fatty acids in cardiovascular medicine
In subjects with cardiovascular risk factors or in patients in need of secondary prevention, hypertriglyceridemia is a well-defined risk factor for adverse cardiac events. Drugs containing n-3 polyunsaturated fatty acids (n-3 PUFAs) are approved for treatment of hypertriglyceridemia. In 1999, a card...
Autores principales: | Ferrari, Roberto, Censi, S, Cimaglia, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537797/ https://www.ncbi.nlm.nih.gov/pubmed/33061867 http://dx.doi.org/10.1093/eurheartj/suaa118 |
Ejemplares similares
-
Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits?
por: Bowen, Kate J., et al.
Publicado: (2016) -
Metabolic syndrome cardiovascular risk prevention by omega-3 polyunsaturated fatty acids
por: Bäck, Magnus, et al.
Publicado: (2023) -
Omega 3 Fatty Acids vs Omega 6 Fatty Acids
por: Feliu, María, et al.
Publicado: (2022) -
An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health
por: Elagizi, Andrew, et al.
Publicado: (2021) -
Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health
por: Rodriguez, Daniel, et al.
Publicado: (2022)